Affiliations: [a] Department of Neurology, San Carlos Institute for Health Research (IdISSC), Universidad Complutense, Madrid, Spain
| [b] Department of Psychiatry and Behavioral Sciences, Miller School of Medicine, University of Miami and Center of Aging, Miami, FL, USA
Correspondence:
[*]
Correspondence to: Jordi A. Matias-Guiu, Department of Neurology, Hospital Clínico San Carlos, Prof. Martín Lagos St., 28040 Madrid, Spain. Tel.: +34 913303511, 676933312; Emails: [email protected], [email protected].
Abstract: Background: The Loewenstein-Acevedo Scale for Semantic Interference and Learning (LASSI-L) is a novel cognitive test that measures recovery from proactive semantic interference, which may be an early cognitive marker of Alzheimer’s disease (AD). Objective: To generate normative data for a Spaniard population and to validate the LASSI-L for the diagnosis of amnestic mild cognitive impairment (aMCI) and mild AD. Methods: We performed a cross-sectional study in which 97 healthy participants, 34 with aMCI, and 33 with mild AD were studied with LASSI-L and a comprehensive neuropsychological protocol. The overlapping strategy analysis was used to maximize the sample size and to provide age- and education-adjusted normative data using a logistic regression analysis. Results: Internal consistency was 0.932. Convergent validity with the Free and Cued Selective Reminding Test was moderate. LASSI-L raw scores were correlated with age and years of education, but not gender. The area under the curve for discriminating between healthy controls and aMCI was 0.909, and between healthy controls and mild AD was 0.986. LASSI-L sub-scores representing maximum storage capacity, recovery from proactive interference, and delayed recall yielded the highest diagnostic accuracy. Conclusions: The LASSI-L is a reliable and valid test for the diagnosis of aMCI and mild AD. The age and education influences on the performance of the test and normative data are provided. LASSI-L merits further studies to evaluate its ability to detect preclinical AD and predict progression to aMCI and early dementia.
